US-based medical device maker NinePoint Medical has closed $34m in series B financing led by glass and ceramics maker Corning Incorporated.
NinePoint Medial works to improve patient care through the development of medical devices that enable high-resolution in-vivo imaging. The latest financing round also saw re-investment from venture capital firms Third Rock Ventures and Prospect Venture Partners, both existing investors.
The series B round brings NinePoint’s total funding to $67m. The company also announced the addition of three new members to its board of directors: Curt Weinstein from Corning and independent directors Tom Miller and Mark Stautberg.
Charles S. Carignan, MD, president and chief executive of NinePoint Medical, said: “With new hospitals adopting the technology every month, and with the support of our investors and strategic guidance of our board, we can continue to expand our sales force to facilitate the adoption of NvisionVLE at more centres.
“Hospitals from New England, to Florida, to California are already offering this advanced imaging technology. We will continue to build out our operational capacity to meet the increasing demand for our products, while also working on new features and product offerings for the future.”
Proceeds from the financing will support the ongoing commercial launch of the NvisionVLE Imaging System in the US, as well as development of the company’s product offering.
The new additions to the board of directors bring a wealth of experience. Tom Miller has previously held senior positions with Siemens, Carl Zeiss, Analogic Corporation and LightLab Imaging. Mark Stautberg has more than 30 years of medical device sales and marketing experience from Boston Scientific Corporation and Baxter Healthcare and currently serves as a director on the board of Baxano Surgical.